Research Shows Recombinant Pure PDGF Improves Aesthetic Results, Patient Satisfaction Following RF Microneedling

Research published in the Journal of Cosmetic Dermatology evaluates the efficacy and safety of topical application of pure platelet-derived growth factor (PDGF) compared with standard of care following radiofrequency (RF) microneedling. 

A prospective, evaluator-blinded, randomized, controlled clinical trial investigated subjects aged 30 to 60 who received a single RF microneedling treatment, followed by application of either standard of care (Aquaphor) or pure PDGF. 

Participants were evaluated on days 7 and 30 postprocedure by a board-certified dermatologist using the Clinical Global Aesthetic Improvement Score (CGAIS), and by Canfield Image Analysis (IA) software which assessed 7 aesthetic parameters. Patient-reported outcome measures (PROMs) were also obtained on days 7 and 30 following treatment. 

The clinical trial found that pure PDGF treatment resulted in greater improvement in the CGAIS at days 7 and 30 compared with the standard of care group. Additionally, PDGF treatment outperformed the standard of care group in 6 of 7 outcomes in image analysis. PROMs indicated that participants receiving standards of care. No serious adverse effects were reported. 

Investigators concluded the clinical trial shows the application of pure PDGF possesses an excellent safety profile and improves facial skin quality 30 days post RF microneedling more effectively than the current standard of care.